In the BioHarmony Drug Report Database

"Preview" Icon

Pazopanib

Votrient (pazopanib) is a small molecule pharmaceutical. Pazopanib was first approved as Votrient on 2009-10-19. It is used to treat renal cell carcinoma and soft tissue neoplasms in the USA. It has been approved in Europe to treat renal cell carcinoma. The pharmaceutical is active against vascular endothelial growth factor receptor 1, vascular endothelial growth factor receptor 2, and vascular endothelial growth factor receptor 3. In addition, it is known to target mast/stem cell growth factor receptor Kit, fibroblast growth factor receptor 1, platelet-derived growth factor receptor beta, and macrophage colony-stimulating factor 1 receptor. Votrient’s patent is valid until 2023-10-19 (FDA).

 

Trade Name

 

Votrient
 

Common Name

 

pazopanib
 

ChEMBL ID

 

CHEMBL477772
 

Indication

 

renal cell carcinoma, soft tissue neoplasms
 

Drug Class

 

Angiogenesis inhibitors

Image (chem structure or protein)

Pazopanib structure rendering